Recent Quotes (30 days)

You have no recent quotes
chg | %

Victrex plc  

(Public, LON:VCT)   Watch this stock  
Find more results forVCT
1,609.35
+0.35 (0.02%)
Jun 19 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 1,592.00 - 1,618.00
52 week 1,164.00 - 1,791.00
Open 1,611.00
Vol / Avg. 106,588.00/152,048.00
Mkt cap 1,363.94M*
P/E 18.90
Div/yield 10.35/2.41*
EPS 0.85*
Shares 84.75M
Beta     -
Inst. own     -
*GBP
Jul 25, 2013
Victrex PLC Second Interim Management Statement covering the period from 1 April 2013 Add to calendar
May 28, 2013
Interim 2013 Victrex PLC Earnings Conference Call
Apr 9, 2013
Victrex PLC Trading Update for the six months ended 31 March 2013 Conference Call
Apr 9, 2013
Victrex PLC Trading Update for the six months to 31 March 2013
  

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 32.99% 32.71%
Operating margin 42.67% 42.77%
EBITD margin - 47.13%
Return on average assets 21.17% 23.44%
Return on average equity 25.69% 29.19%
Employees 607 -
Carbon Disclosure Rating - -

Address

Victrex Technology Centre Hillhouse International Thornton Cleveleys
THORNTON CLEVELEYS, ENG FY5 4QD
United Kingdom - Map
+44-1253-897700 (Phone)
+44-1253-897701 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance
Discussion Group - Google Finance

Description

Victrex plc is a holding company. The Company is a manufacturer of high-performance polyaryletherketones, including VICTREX PEEK polymer. Its business is organized as two business units: Victrex Polymer Solutions (VPS) and Invibio Biomaterial Solutions (Invibio). VPS provides a range of products, together with technical and marketing support to its customers and end users to help them deliver new, cost effective solutions in its markets of industrial, transport and electronics. Invibio provides versatile PEEK-based polymers to address the needs of the long-term implantable medical device market. Its materials are used across a number of applications, including spinal fusion and motion preservation, arthroscopy, joint replacement, trauma, cardio-neuro and cranio-maxillo facial implants. The Company�s subsidiaries include Victrex Manufacturing Limited, invibio Limited, Victrex Japan, Inc. Victrex USA, Inc. and Invibio USA, Inc.

Officers and directors

David R. Hummel Chief Executive, Executive Director
A. Steve Barrow Group Finance Director, Executive Director
Suzana Koncarevic General Counsel, Company Secretary
Tim J. Cooper Executive Director
Anita M. Frew Non-Executive Independent Chairman of the Board
Age: 55
Patrick J. M. De Smedt Non-Executive Independent Director
Giles F. B. Kerr Senior Non-Executive Independent Director
Age: 53
Pamela J. Kirby Ph.D. Non-Executive Independent Director
Age: 59
Lawrence C. Pentz Non-Executive Independent Director